DNAprint Genomics (DNAG)

[Bill H]

(PR NEWSWIRE) DNAPrint(TM) Participates in the TBTF and BioFlorida Tampa Bay Pa
tnering Conference Thursday, April 1, 2004
DNAPrint(TM) Participates in the TBTF and BioFlorida Tampa Bay Partnering Confer
nce Thursday, April 1, 2004

SARASOTA, Fla., March 17 /PRNewswire-FirstCall/ -- DNAPrint's CEO and
President is presenting at the combined Tampa Bay Technology Forum and
BioFlorida Tampa Bay partnering conference on April 1, 2004 at the Hyatt
Sarasota, 1000 Blvd. of the Arts, Sarasota, Florida. The presentation will
include a description of DNAPrint(TM)'s technology and market applications.
The presentation will highlight the four market segments in which DNAPrint(TM)
applies its proprietary Single Nucleotide Polymorphism (SNP) screening
technology: 1) genealogy; featuring its latest released product
ANCESTRYbyDNA(TM) 2.5 used by genealogists and families to help understand
their genetic heritage; 2) forensics; featuring its flagship product
DNAWitness(TM) 2.0, which was introduced and first used in the first quarter
of 2003 and has since helped detectives and investigators in two high-profile
cases, the Louisiana serial killer case (2003) and the Concord, California
case; 3) pharmacogenomics; the company is working with a Florida institution
to advance its technology (known as Ovanome(TM)) and to combine its technology
with other genetic methods to help reduce the risk of cancer treatment; and 4)
contract genotyping; the company has developed a strong reputation as a
reliable and cost-effective contract genotyping service and continues to
supply medical centers and universities with this service.
"We see the forum as a means to advance our company and improve
shareholder value through partnering opportunities that might present
themselves at this conference," said Richard Gabriel, CEO and President of
DNAPrint(TM) genomics, Inc. "Over the last year we have been relatively quiet.
We have spent this time reorganizing the company and advancing our
technologies. We are seeking partners in all three commercial areas,
genealogy, forensics and pharmacogenomics, and that could include partners in
a variety of structures. We have just finished an $8.0 million financing
round, and the proceeds from that transaction have been flowing into the
company at a steady rate. This is the fuel that we need to build the business
and advance the technology, and we are doing that."
"The company's senior management will continue to explore all
opportunities, and we believe these partnering forums are a great vehicle for
allowing companies to exchange ideas and seek new opportunities," said Hector
Gomez, MD, PhD, Chairman of the Board and Chief Medical Officer. "Our joining
BioFlorida and being involved with the Sarasota business community is another
step in advancing our technology and company," he said.
"Sarasota and the Tampa Bay area are a rapidly emerging biotechnology
center, and we were one of the first life-science companies to start up in
Sarasota -- well, certainly one of the first genetics companies," said Tony
Frudakis, PhD. "We're excited about the partnering opportunities that might
exist in our own backyard."

About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics, Inc. was founded by a team of scientists with
research and commercial experience in high-level mathematical modeling,
programming and molecular genetics. The DNAWitness(TM) and the
ANCESTRYbyDNA(TM) analysis is a direct result of focused research by the DNAP
research and development team.
In addition, using proprietary human genome research methods, the Company
develops pharma-predictive tests for matching patients with drugs based on
their genetic constitution, discovers disease genes for the development of new
drugs and develops new forensic genomics and consumer genomics testing
products. The Company is traded on the Nasdaq OTC Bulletin Board under the
ticker symbol: DNAP. For more information about the company, please visit
www.dnaprint.com.
For more information on our genealogical DNA-derived test,
ANCESTRYbyDNA(TM) 2.5, visit us on line at www.ancestrybydna.com helping
everyone to understand their genetic heritage.

All statements in this press release that are not historical and are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's(TM) products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's(TM) expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
[phone]

SOURCE DNAPrint(TM) genomics, Inc.
-0- 03/17/2004
/CONTACT: Richard Gabriel, CEO - President, DNAPrint(TM) genomics,
[phone]/
/Web site: http://www.dnaprint.com
http://www.ancestrybydna.com /
(DNAP)

CO: DNAPrint(TM) genomics, Inc.
ST: Florida
IN: MTC OTC
SU:
*** end of story ***